Chemotherapy Induced Peripheral Neuropathy – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Chemotherapy Induced Peripheral Neuropathy – Pipeline Review, H2 2018’, provides an overview of the Chemotherapy Induced Peripheral Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy

– The report reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Chemotherapy Induced Peripheral Neuropathy therapeutics and enlists all their major and minor projects

– The report assesses Chemotherapy Induced Peripheral Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achelios Therapeutics Inc

Aptinyx Inc

Asahi Kasei Corp

Can-Fite BioPharma Ltd

Celgene Corp

Immune Pharmaceuticals Inc

Insys Therapeutics Inc

Kineta Inc

Kyorin Pharmaceutical Co Ltd

Mundipharma International Ltd

Nemus Bioscience Inc

Neurocentrx Pharma Ltd

PeriphaGen Inc

PledPharma AB

Sensei Biotherapeutics Inc

Sova Pharmaceuticals Inc

Trevena Inc

WEX Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Chemotherapy Induced Peripheral Neuropathy Overview 6

Chemotherapy Induced Peripheral Neuropathy Therapeutics Development 7

Chemotherapy Induced Peripheral Neuropathy Therapeutics Assessment 15

Chemotherapy Induced Peripheral Neuropathy Companies Involved in Therapeutics Development 23

Chemotherapy Induced Peripheral Neuropathy Drug Profiles 32

Chemotherapy Induced Peripheral Neuropathy Dormant Projects 123

Chemotherapy Induced Peripheral Neuropathy Discontinued Products 125

Chemotherapy Induced Peripheral Neuropathy Product Development Milestones 126

Appendix 136

List of Tables

List of Tables

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Chemotherapy Induced Peripheral Neuropathy Pipeline by Achelios Therapeutics Inc, H2 2018

Chemotherapy Induced Peripheral Neuropathy Pipeline by Aptinyx Inc, H2 2018

Chemotherapy Induced Peripheral Neuropathy Pipeline by Asahi Kasei Corp, H2 2018

Chemotherapy Induced Peripheral Neuropathy Pipeline by Can-Fite BioPharma Ltd, H2 2018

Chemotherapy Induced Peripheral Neuropathy Pipeline by Celgene Corp, H2 2018

Chemotherapy Induced Peripheral Neuropathy Pipeline by Immune Pharmaceuticals Inc, H2 2018

Chemotherapy Induced Peripheral Neuropathy Pipeline by Insys Therapeutics Inc, H2 2018

Chemotherapy Induced Peripheral Neuropathy Pipeline by Kineta Inc, H2 2018

Chemotherapy Induced Peripheral Neuropathy Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018

Chemotherapy Induced Peripheral Neuropathy Pipeline by Mundipharma International Ltd, H2 2018

Chemotherapy Induced Peripheral Neuropathy Pipeline by Nemus Bioscience Inc, H2 2018

Chemotherapy Induced Peripheral Neuropathy Pipeline by Neurocentrx Pharma Ltd, H2 2018

Chemotherapy Induced Peripheral Neuropathy Pipeline by PeriphaGen Inc, H2 2018

Chemotherapy Induced Peripheral Neuropathy Pipeline by PledPharma AB, H2 2018

Chemotherapy Induced Peripheral Neuropathy Pipeline by Sensei Biotherapeutics Inc, H2 2018

Chemotherapy Induced Peripheral Neuropathy Pipeline by Sova Pharmaceuticals Inc, H2 2018

Chemotherapy Induced Peripheral Neuropathy Pipeline by Trevena Inc, H2 2018

Chemotherapy Induced Peripheral Neuropathy Pipeline by WEX Pharmaceuticals Inc, H2 2018

Chemotherapy Induced Peripheral Neuropathy Dormant Projects, H2 2018

Chemotherapy Induced Peripheral Neuropathy Dormant Projects, H2 2018 (Contd..1), H2 2018

Chemotherapy Induced Peripheral Neuropathy Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports